Several factors including ITPA polymorphism influence ribavirin-induced anemia in chronic hepatitis C

World J Gastroenterol. 2012 Nov 7;18(41):5879-88. doi: 10.3748/wjg.v18.i41.5879.

Abstract

Aim: To construct formulae for predicting the likelihood of ribavirin-induced anemia in pegylated interferon α plus ribavirin for chronic hepatitis C.

Methods: Five hundred and sixty-one Japanese patients with hepatitis C virus genotype 1b who had received combination treatment were enrolled and assigned randomly to the derivation and confirmatory groups. Single nucleotide polymorphisms at or nearby ITPA were genotyped by real-time detection polymerase chain reaction. Factors influencing significant anemia (hemoglobin concentration < 10.0 g/dL at week 4 of treatment) and significant hemoglobin decline (declining concentrations > 3.0 g/dL at week 4) were analyzed using multiple regression analyses. Prediction formulae were constructed by significantly independent factors.

Results: Multivariate analysis for the derivation group identified four independent factors associated with significant hemoglobin decline: hemoglobin decline at week 2 [P = 3.29 × 10(-17), odds ratio (OR) = 7.54 (g/dL)], estimated glomerular filtration rate [P = 2.16 × 10(-4), OR = 0.962 (mL/min/1.73 m(2))], rs1127354 (P = 5.75 × 10(-4), OR = 10.94) and baseline hemoglobin [P = 7.86 × 10(-4), OR = 1.50 (g/dL)]. Using the model constructed by these factors, positive and negative predictive values and predictive accuracy were 79.8%, 88.8% and 86.2%, respectively. For the confirmatory group, they were 83.3%, 91.0% and 88.3%. These factors were closely correlated with significant anemia. However, the model could not be constructed, because no patients with rs1127354 minor genotype CA/AA had significant anemia.

Conclusion: Reliable formulae for predicting the likelihood of ribavirin-induced anemia were constructed. Such modeling may be useful in developing individual tailoring and optimization of ribavirin dosage.

Keywords: Chronic hepatitis C virus infection; Hemolytic anemia; Pegylated interferon α; Prediction model; Ribavirin; Single nucleotide polymorphism.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Anemia / blood
  • Anemia / chemically induced*
  • Anemia / enzymology
  • Anemia / genetics*
  • Antiviral Agents / adverse effects*
  • Biomarkers / blood
  • Chi-Square Distribution
  • Drug Therapy, Combination
  • Female
  • Genetic Predisposition to Disease
  • Hemoglobins / metabolism
  • Hepatitis C, Chronic / diagnosis
  • Hepatitis C, Chronic / drug therapy*
  • Humans
  • Interferon alpha-2
  • Interferon-alpha / therapeutic use
  • Japan
  • Logistic Models
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Odds Ratio
  • Phenotype
  • Polyethylene Glycols / therapeutic use
  • Polymorphism, Single Nucleotide*
  • Pyrophosphatases / genetics*
  • Recombinant Proteins / therapeutic use
  • Ribavirin / adverse effects*
  • Risk Assessment
  • Risk Factors

Substances

  • Antiviral Agents
  • Biomarkers
  • Hemoglobins
  • Interferon alpha-2
  • Interferon-alpha
  • Recombinant Proteins
  • Polyethylene Glycols
  • Ribavirin
  • Pyrophosphatases
  • ITPA protein, human
  • peginterferon alfa-2b
  • peginterferon alfa-2a